Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of biosimilar ustekinumab FYB202 vs Stelara in moderate-to-severe plaque psoriasis
2019-004364-21Phase 3Completed
- Sponsor
- Bioeq AG
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis and psoriasis comparing FYB202 biosimilar ustekinumab with Reference ustekinumab (Stelara) (2 arms). Primary endpoint: Percent improvement in PASI score from baseline to week 12. Started Mar 2020; status: completed.
02
Drugs
ustekinumabustekinumab-aauz
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2019-004364-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004364-21.